EAT is up +49.38%% since April’24 pick View All Top Buy Picks

3 Magic Formula Health Care Stock Picks

11:41am, Monday, 19'th Apr 2021
If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
Blueprint Medicines is setting itself up to become the leader in precision oncology.
CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) pro
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precis
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera
CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the
The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.
Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q4 2020 Results - Earnings Call Transcript
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Recap: Blueprint Medicines Q4 Earnings

07:36am, Wednesday, 17'th Feb 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimat
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. Effective
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE